Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study of HEMO-CAR-T therapy in pediatric acute myeloid leukemia and pediatric acute lymphoblastic leukemia

Trial Profile

Study of HEMO-CAR-T therapy in pediatric acute myeloid leukemia and pediatric acute lymphoblastic leukemia

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 27 Sep 2024 According to a Hemogenyx Pharmaceuticals media release, company is looking forward for this clinical trials expected to begin shortly at M.D. Anderson Cancer Center in Texas
  • 18 Jun 2024 New trial record
  • 17 Jun 2024 According to a Hemogenyx Pharmaceuticals media release, company is seeking to expand the HEMO-CAR-T indication to include pediatric acute myeloid leukemia and a subset of pediatric acute lymphoblastic leukemia patients. An amendment to the clinical protocol to include pediatric AML is currently under review by third party experts. If approved, the Company will seek to implement the clinical trials for pediatric AML at the newly established clinical site.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top